• B Suberviola, E Rodrigo, A González-Castro, M Serrano, M Heras, and Á Castellanos-Ortega.
• Intensive Care Department, University Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain. Electronic address: bsuberviola@yahoo.es.
• Med Intensiva. 2017 Jan 1; 41 (1): 21-27.

ObjectiveTo evaluate the association between angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) use prior to a septic shock episode and the development, prognosis and long-term recovery from acute kidney injury (AKI).DesignA single-centre, prospective observational study was carried out between September 2005 and August 2010.ScopePatients admitted to the ICU of a third level hospital.PatientsA total of 386 septic shock patients were studied.InterventionsNone.Variables Of InterestUse of ACEIs/ARBs, AKI development, recovery of previous creatinine levels and time to recovery.ResultsA total of 386 patients were included, of which 312 (80.8%) developed AKI during ICU stay and 23% were receiving ACEIs/ARBs. The percentage of patients on ACEIs/ARBs increased significantly in relation to more severe stages of AKI irrespective of the kind of AKI score. After adjusting for confounders, the development of AKI was independently associated to the use of ACEIs/ARBs (OR 2.19; 95%CI 1.21-3.84; p=.04). With respect to the recovery of kidney function, the group of patients on ACEIs/ARBs had significantly higher creatinine levels at ICU discharge and needed hemodialysis more frequently thereafter. However, use of ACEIs/ARBs affected neither recovery of previous creatinine levels nor significantly delayed recovery.ConclusionsThe use of ACEIs/ARBs before septic shock episodes was correlated to AKI development and severity, but did not affect the recovery of kidney function after sepsis resolution.Copyright © 2016 Elsevier España, S.L.U. y SEMICYUC. All rights reserved.

7 keywords...

hide…